别嘌醇剂量上调与痛风患者死亡率:一项全国倾向匹配队列研究
该研究纳入美国退伍军人痛风患者,采用倾向评分匹配、Cox比例风险模型和竞争风险回归,比较2年内别嘌醇剂量上调者与未上调或减量者的死因别死亡率。在6,428对匹配患者中,剂量上调与全因死亡率轻度增加相关(HR 1.08,95%CI 1.01-1.17),心血管和癌症相关死亡未达统计学显著。
要点
- 剂量上调者全因死亡率较未上调或减量者轻度增加(HR 1.08,95%CI 1.01-1.17)。
- 心血管相关死亡(HR 1.08,95%CI 0.97-1.21)和癌症相关死亡(HR 1.06,95%CI 0.88-1.27)未达统计学显著。
- 2年时仅10%剂量上调者最终日剂量>300 mg,31%达到血清尿酸<6.0 mg/dl目标。
核心结论
- 这是迄今最大规模研究别嘌醇使用对死亡率影响的研究,也是首个采用严格活性对照设计的研究。
- 剂量上调与全因死亡率轻度(<10%)增加相关,表明在现实实践中以有限剂量增加为特征的别嘌醇剂量上调策略不太可能改善痛风患者生存。
研究设计与样本
- 10年观察性活性对照研究,纳入开始别嘌醇治疗的美国退伍军人痛风患者。
- 采用倾向评分匹配、Cox比例风险模型和竞争风险回归分析,比较2年内别嘌醇剂量上调者与未上调或减量者的死因别死亡率。
- 共匹配6,428例剂量上调者和6,428例未上调或减量者。
主要发现
- 观察期间共发生2,867例死亡(40.4例/1000人年)。
- 剂量上调者全因死亡率增加(HR 1.08,95%CI 1.01-1.17)。
- 心血管相关死亡(HR 1.08,95%CI 0.97-1.21)和癌症相关死亡(HR 1.06,95%CI 0.88-1.27)的效应量相似,但均未达统计学显著。
- 剂量上调至达到血清尿酸<6.0 mg/dl目标的情况不常见;2年时10%剂量上调者最终日剂量>300 mg,31%达到血清尿酸目标。
- 仅在达到血清尿酸目标的剂量上调者中进行的敏感性分析显示,心血管相关死亡风险非显著降低7%(HR 0.93,95%CI 0.76-1.14)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Observational data suggest that hyperuricemia and gout are associated with increased mortality, while allopurinol use is associated with reduced mortality. In addition, the protective effect of allopurinol may be dose dependent. The aim of the current study was to determine whether allopurinol dose escalation is associated with cause-specific mortality in patients with gout. METHODS: In this 10-year observational, active-comparator study of US Veterans with gout who initiated treatment with allopurinol, propensity score matching, Cox proportional hazards models, and competing risks regression analyses were used to assess differences in cause-specific mortality between patients whose allopurinol dose was escalated (dose escalators) and those whose allopurinol dose was not escalated or was reduced (non-escalators) over a 2-year period. RESULTS: Among the 6,428 dose escalators and 6,428 matched non-escalators, there were 2,867 deaths during the observation period (40.4 deaths per 1,000 person-years). Dose escalators experienced an increase in all-cause mortality (hazard ratio [HR] 1.08, 95% confidence interval [95% CI] 1.01-1.17), with the effect sizes being similar for incidence of cardiovascular-related deaths (HR 1.08, 95% CI 0.97-1.21) and cancer-related deaths (HR 1.06, 95% CI 0.88-1.27), although neither reached statistical significance. Dose escalation to achieve the goal of lowering the serum urate (SU) level to <6.0 mg/dl was infrequent. At 2 years, 10% of dose escalators were receiving a final daily dose of >300 mg and 31% had achieved the SU goal. In a sensitivity analysis limited to dose escalators achieving the SU goal, there was a nonsignificant reduction of 7% in the hazard of cardiovascular-related mortality (HR 0.93, 95% CI 0.76-1.14). CONCLUSION: This is the largest study to date to investigate the effects of allopurinol use on mortality and is the first to use a rigorous active-comparator design. Dose escalation was associated with a small (<10%) increase in all-cause mortality, thus showing that a strategy of allopurinol dose escalation, which in current real-life practice is characterized by limited dose increases, is unlikely to improve the survival of patients with gout.
引用
- Coburn BW, Michaud K, Bergman DA, et al. Allopurinol Dose Escalation and Mortality Among Patients With Gout: A National Propensity-Matched Cohort Study. Arthritis Rheumatol. 2018. PMID: 29513934. doi:10.1002/art.40486
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。